Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to represent a significant advancement for body treatment. Early human investigations have indicated considerable losses in body tissue, possibly exceeding current body composition therapies . Nevertheless , further